Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Bulk Ink Refill Bottles for Epson
Popular Articles

Recession Taking Toll On Unemployed As Well As Caregivers
The recession has increased the number of uninsured Americans and made it more difficult to access health care programs while also placing special burdens on caregivers.

Health Information Technology And Health Care Reform Must Be Well-Aligned To Improve Health And Lower Costs
Dramatic improvements in health and reductions in cost growth are achievable if efforts to boost health information technology (IT) are aligned with broader health care reform, a group of three influential non-profit organizations said today.
News of the day
1957-58 Flu Pandemic Can Provide Clues To Planning For H1N1
As the U.S. prepares for a resurgence of H1N1 influenza this fall, much can be learned from looking at a previous pandemic that had similar patterns. In an article published today in Biosecurity and Bioterrorism, researchers at the Center for Biosecurity of the University of Pittsburgh Medical Center (UPMC) examined historical documents, published material, and newspaper coverage related to the 1957-58 influenza pandemic to compare the progress and severity of that outbreak with the current one. The simple, practical actions taken in 1957 allowed the country to continue functioning with minimal disruption.
Health Insurance

GTx-758, An Oral LH Inhibitor For First Line Treatment Of Advanced Prostate Cancer, Advances Into Second Phase I Clinical Trial

GTx, Inc. (Nasdaq: GTXI), announced the initiation of a Phase I multiple ascending dose clinical trial evaluating GTx-758, an oral LH inhibitor for first line treatment of advanced prostate cancer. A Phase I single ascending dose clinical trial in 96 subjects was successfully completed in June. In the completed Phase I single ascending dose clinical trial, GTx-758 was well tolerated. GTx-758 demonstrated a pharmacokinetic profile compatible with once daily oral dosing and systemic exposures increasing with dose. The ongoing Phase I multiple ascending dose clinical trial is an open label, single center study of five dose groups of GTx-758, with ten healthy male subjects per group each receiving doses for 10 days. The study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758. In addition, testosterone and other hormones will be measured to assess the activity of GTx-758 on hormones secreted by the pituitary, hypothalamus, and adrenal glands. "In this clinical trial, we expect to establish proof of the ability of GTx-758 to reduce testosterone, which is the endpoint required for primary androgen deprivation therapy clinical trials," said GTx CEO Mitchell S. Steiner, MD. GTx expects to complete this Phase I multiple ascending dose clinical trial in the fourth quarter. About GTx-758 GTx-758 is an oral LH inhibitor which GTx is developing for the treatment of advanced prostate cancer. Preclinical in vitro and in vivo data suggest GTx-758 rapidly suppresses secretion of LH, thereby inhibiting production of androgens by the testes. GTx believes GTx-758 has the potential to reduce testosterone, a primary growth factor of prostate cancer, without causing bone loss and hot flashes. Prostate cancer is the second most common type of cancer diagnosed in men in the U.S. An estimated 186,000 new cases of prostate cancer were diagnosed in the U.S. in 2008. Approximately 700,000 men with prostate cancer are being treated with androgen deprivation therapy (ADT) and an estimated 100,000 initiate ADT each year. Annual US sales of drugs for ADT exceeded $1.7 billion in 2008. GTx, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009